Sign In
to Vote &
Create Storyboards.
 
BioTime Makes Key Clinical Progress; SOTP Now $4.40/Share BioTime announced plan to spin-off AgeX Therapeutics. The separation is expected to occur during the end of September 2018. Spin-Off Research, founded by Joe Cornell, has tracked and provided analysis on Spin-Offs since 1997. Spin-Off Research is the market leader in Spin-Off valuation.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard